• United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares at USD 146.03 on May 14, 2026.
• Rothblatt sold 9,500 shares in same session at prices ranging from USD 568.69 to USD 578.29.
• Directly owned common shares ended day at 40,513.
• Rothblatt also reported 230,910 stock options held following transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000054), on May 15, 2026, and is solely responsible for the information contained therein.